Assessment of microRNA expression as a regulator in the serum of patients with colorectal cancer

The present research investigates the treatment and colorectal cancer prevention by altering the growth factors present in the patient's RNA with colorectal cancer. We first prepare serum from blood samples taken from patients, then we remove the serum supernatant and incubate it with the kit solution; after centrifugation, the pellet containing the exosome is dissolved in PBS. To photograph the exosome by electron microscopy, we prepare the slide. For preparing the slide, we randomly removed it from a healthy sample and transferred it to a vial. We inserted the prepared vials into a sonicator, after drying the samples covered them with a thin layer of gold and used electron microscopy for the size and morphology of the exosomes. After isolating the RNAs, we recorded their information on a computer and performed polyadenylation and single-stranded cDNA synthesis. We proliferated the target DNA by real-time PCR. Finally, we used Excel software and a T-test for statistical analysis of the data. The results showed that the normalized expression ratio of miRNA140 in the serum exosome of colon carcinoma was significantly lower than the normal serum exosome (p <0.001). The result is consistent with the tumor-suppressor function of this miRNA, which regulates the growth factor pathway of the beta-modifier. Therefore, it seems that the amount of microRNA 140 expression and its accumulation in the exosome is associated with the stage progression of the disease as well as the metastasis of cancer cells to the lymph nodes.